• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

过氧化物酶体增殖物激活受体α/γ双重激动剂GL479的不同结合和识别模式

Different binding and recognition modes of GL479, a dual agonist of Peroxisome Proliferator-Activated Receptor α/γ.

作者信息

dos Santos Jademilson Celestino, Bernardes Amanda, Giampietro Letizia, Ammazzalorso Alessandra, De Filippis Barbara, Amoroso Rosa, Polikarpov Igor

机构信息

Grupo de Biotecnologia Molecular, Instituto de Física de São Carlos, Universidade de São Paulo, São Carlos, SP 13566-590, Brazil.

Dipartimento di Farmacia, Università degli Studi 'G. d'Annunzio', via dei Vestini 31, 66100 Chieti, Italy.

出版信息

J Struct Biol. 2015 Sep;191(3):332-40. doi: 10.1016/j.jsb.2015.07.006. Epub 2015 Jul 14.

DOI:10.1016/j.jsb.2015.07.006
PMID:26185032
Abstract

Peroxisome Proliferator-Activated Receptors (PPARs) are ligand-dependent transcription factors that control various functions in human organism, including the control of glucose and lipid metabolism. PPARγ is a target of TZD agonists, clinically used to improve insulin sensitivity whereas fibrates, PPARα ligands, lower serum triglyceride levels. We report here the structural studies of GL479, a synthetic dual PPARα/γ agonist, designed by a combination of clofibric acid skeleton and a phenyldiazenyl moiety, as bioisosteric replacement of stilbene group, in complex with both PPARα and PPARγ receptors. GL479 was previously reported as a partial agonist of PPARγ and a full agonist of PPARα with high affinity for both PPARs. Our structural studies reveal different binding modes of GL479 to PPARα and PPARγ, which may explain the distinct activation behaviors observed for each receptor. In both cases the ligand interacts with a Tyr located at helix 12 (H12), resulting in the receptor active conformation. In the complex with PPARα, GL479 occupies the same region of the ligand-binding pocket (LBP) observed for other full agonists, whereas GL479 bound to PPARγ displays a new binding mode. Our results indicate a novel region of PPARs LBP that may be explored for the design of partial agonists as well dual PPARα/γ agonists that combine, simultaneously, the therapeutic effects of the treatment of insulin resistance and dyslipidemia.

摘要

过氧化物酶体增殖物激活受体(PPARs)是依赖配体的转录因子,可控制人体多种功能,包括葡萄糖和脂质代谢的调控。PPARγ是噻唑烷二酮类(TZD)激动剂的作用靶点,临床上用于提高胰岛素敏感性,而贝特类药物(PPARα配体)则可降低血清甘油三酯水平。我们在此报告了GL479的结构研究,GL479是一种合成的双PPARα/γ激动剂,由氯贝酸骨架和苯基二氮烯基部分组合设计而成,作为芪基的生物电子等排体替代物,与PPARα和PPARγ受体形成复合物。GL479此前被报道为PPARγ的部分激动剂和PPARα的完全激动剂,对两种PPARs都具有高亲和力。我们的结构研究揭示了GL479与PPARα和PPARγ的不同结合模式,这可能解释了每种受体观察到的不同激活行为。在这两种情况下,配体都与位于螺旋12(H12)的酪氨酸相互作用,从而导致受体的活性构象。在与PPARα形成的复合物中,GL479占据了其他完全激动剂所观察到的配体结合口袋(LBP)的相同区域,而与PPARγ结合的GL479则呈现出一种新的结合模式。我们的结果表明,PPARs的LBP有一个新区域,可用于设计部分激动剂以及同时结合胰岛素抵抗和血脂异常治疗效果的双PPARα/γ激动剂。

相似文献

1
Different binding and recognition modes of GL479, a dual agonist of Peroxisome Proliferator-Activated Receptor α/γ.过氧化物酶体增殖物激活受体α/γ双重激动剂GL479的不同结合和识别模式
J Struct Biol. 2015 Sep;191(3):332-40. doi: 10.1016/j.jsb.2015.07.006. Epub 2015 Jul 14.
2
Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.过氧化物酶体增殖物激活受体γ(PPARγ)配体结合域与新型部分激动剂复合的晶体结构:疏水口袋的一个新区域可用于药物设计。
J Med Chem. 2008 Dec 25;51(24):7768-76. doi: 10.1021/jm800733h.
3
Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.作为一种 PPARα/γ双重激动剂,用于治疗非酒精性脂肪性肝病和糖尿病血脂异常的药物沙格列汀的结构基础。
Biol Pharm Bull. 2021;44(9):1210-1219. doi: 10.1248/bpb.b21-00232.
4
Identification and characterization of phytocannabinoids as novel dual PPARα/γ agonists by a computational and in vitro experimental approach.通过计算和体外实验方法鉴定和表征植物大麻素作为新型双重 PPARα/γ激动剂。
Biochim Biophys Acta Gen Subj. 2019 Mar;1863(3):586-597. doi: 10.1016/j.bbagen.2019.01.002. Epub 2019 Jan 3.
5
Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.具有PPARα和PPARγ激动剂活性的新型手性贝特类药物的合成、生物学评价及分子模拟研究
J Med Chem. 2005 Aug 25;48(17):5509-19. doi: 10.1021/jm0502844.
6
PPAR dual agonists: are they opening Pandora's Box?过氧化物酶体增殖物激活受体双重激动剂:它们是否在打开潘多拉魔盒?
Pharmacol Res. 2007 Aug;56(2):91-8. doi: 10.1016/j.phrs.2007.03.002. Epub 2007 Mar 14.
7
Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?鱼油中的ω-3长链脂肪酸及其衍生物是过氧化物酶体增殖物激活受体激动剂吗?
Cardiovasc Diabetol. 2008 Mar 20;7:6. doi: 10.1186/1475-2840-7-6.
8
Identification of novel PPARα/γ dual agonists by virtual screening, ADMET prediction and molecular dynamics simulations.通过虚拟筛选、ADMET 预测和分子动力学模拟鉴定新型 PPARα/γ 双重激动剂。
J Biomol Struct Dyn. 2018 Aug;36(11):2988-3002. doi: 10.1080/07391102.2017.1373706. Epub 2017 Oct 5.
9
A rapid, homogeneous, fluorescence polarization binding assay for peroxisome proliferator-activated receptors alpha and gamma using a fluorescein-tagged dual PPARalpha/gamma activator.一种使用荧光素标记的双过氧化物酶体增殖物激活受体α/γ激活剂的快速、均相荧光偏振结合测定法,用于检测过氧化物酶体增殖物激活受体α和γ。
Anal Biochem. 2007 Apr 15;363(2):263-74. doi: 10.1016/j.ab.2007.01.022. Epub 2007 Jan 28.
10
Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.切换亚型选择性:片段替换策略产生了新型的过氧化物酶体增殖物激活受体α/δ(PPARα/δ)双重激动剂。
Bioorg Med Chem Lett. 2017 Jul 15;27(14):3131-3134. doi: 10.1016/j.bmcl.2017.05.037. Epub 2017 May 13.

引用本文的文献

1
Azobenzene as Multi-Targeted Scaffold in Medicinal Chemistry.偶氮苯作为药物化学中的多靶点支架
Molecules. 2024 Dec 12;29(24):5872. doi: 10.3390/molecules29245872.
2
Enhancing Drug Design across Multiple Therapeutic Targets with CVAE Generative Models.利用CVAE生成模型提升针对多个治疗靶点的药物设计
ACS Omega. 2024 Oct 18;9(43):43963-43976. doi: 10.1021/acsomega.4c08027. eCollection 2024 Oct 29.
3
Perfluoroalkyl Acid Binding with Peroxisome Proliferator-Activated Receptors α, γ, and δ, and Fatty Acid Binding Proteins by Equilibrium Dialysis with a Comparison of Methods.
通过平衡透析法研究全氟烷基酸与过氧化物酶体增殖物激活受体α、γ和δ以及脂肪酸结合蛋白的结合,并比较不同方法
Toxics. 2021 Feb 26;9(3):45. doi: 10.3390/toxics9030045.
4
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.芪类衍生的PPAR激动剂的成药特性:理化性质的测定及平行人工膜渗透测定法研究
Medchemcomm. 2019 Aug 15;10(11):1892-1899. doi: 10.1039/c9md00286c. eCollection 2019 Nov 1.
5
Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis.发现一种用于治疗原发性胆汁性肝硬化的新型选择性双过氧化物酶体增殖物激活受体α/δ激动剂。
ACS Med Chem Lett. 2019 Jun 24;10(7):1068-1073. doi: 10.1021/acsmedchemlett.9b00189. eCollection 2019 Jul 11.
6
Novel Phenyldiazenyl Fibrate Analogues as PPAR α/γ/δ Pan-Agonists for the Amelioration of Metabolic Syndrome.新型苯基重氮基贝特类似物作为PPARα/γ/δ泛激动剂用于改善代谢综合征
ACS Med Chem Lett. 2019 Feb 25;10(4):545-551. doi: 10.1021/acsmedchemlett.8b00574. eCollection 2019 Apr 11.
7
Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs.PPARγ 复合物与罗格列酮和吡格列酮的结构揭示了识别抗糖尿病药物的关键决定因素。
Sci Rep. 2017 Dec 4;7(1):16837. doi: 10.1038/s41598-017-17082-x.
8
Arjunolic acid, a peroxisome proliferator-activated receptor α agonist, regresses cardiac fibrosis by inhibiting non-canonical TGF-β signaling.阿朱诺酸,一种过氧化物酶体增殖物激活受体α激动剂,通过抑制非经典转化生长因子-β信号通路来减轻心脏纤维化。
J Biol Chem. 2017 Oct 6;292(40):16440-16462. doi: 10.1074/jbc.M117.788299. Epub 2017 Aug 18.
9
Current Advances in the Biochemical and Physiological Aspects of the Treatment of Type 2 Diabetes Mellitus with Thiazolidinediones.噻唑烷二酮类药物治疗2型糖尿病的生化和生理方面的当前进展
PPAR Res. 2016;2016:7614270. doi: 10.1155/2016/7614270. Epub 2016 May 23.